Buy the Dip Monday: 41% Drawdowns, 11% Earnings Yields, and Net Insider Buying

This Week's Setup

This week's value list is intentionally tight: a biodefense contractor priced like distress, a U.S. solar OEM growing into tariff headlines, and a major gold miner compounding ROIC while metal prices hold.

EBS offers the deepest earnings yield after the drawdown, FSLR splits the difference between growth and multiple compression, and NEM gives a cash-rich hedge with insider tickets that match the ROIC story.

The Three Names

1. Emergent BioSolutions Inc. (EBS)

Stock Pixie Score 8.8/10 (a composite of valuation, income quality, and price recovery signals) | P/E 8.98 | Earnings Yield 11.1% | EV/EBITDA 3.89

The stock trades at 8.98× earnings with an 11.1% earnings yield while generating a 15.8% ROIC, a rare combination in biodefense. Revenue fell 30% year-over-year, but the EV/EBITDA multiple of 3.89 reflects asset value disconnected from near-term sales cycles.

Gross margin of 53.7% is solid for the sector, but the 30% revenue decline signals contract timing risk and government procurement lumpiness that creates quarters of binary outcomes.

Jessica Perl, Coleen Glessner, and Joseph Papa all filed Form 4 transactions in the first week of March, with net selling of 48,191 shares over six months but 2.2% of shares bought in recent activity. Barron's flagged mpox vaccine demand as a catalyst, and the company added John D. Fowler, Jr. to the board this month.

The 41% drawdown puts the stock in deep dip territory, and analyst targets of $12.00 (44% upside) reflect binary approval and contract outcomes that could extend losses if timelines slip.

2. First Solar, Inc. (FSLR)

Stock Pixie Score 8.5/10 | P/E 14.23 | ROIC 22.2% | Revenue Growth 24.1% YoY

The company prints 22.2% ROIC with 40.6% gross margins and grew revenue 24.1% year-over-year, a growth-at-scale profile rarely available at 14.23× earnings. The EV/EBITDA of 8.95 is reasonable for a capital-intensive manufacturer with pricing power.

The 29% drawdown reflects tariff and trade policy uncertainty hitting solar manufacturers, and the stock is down despite revenue acceleration. The normalized P/E (10Y) of 2.69 suggests cyclical earnings compression in prior periods.

Kuntal Kumar Verma, Nathan B. Theurer, and Markus Gloeckler filed Form 4 activity in early March, with net selling of 2,878 shares over six months. Recent news flagged First Solar underperforming the broader market alongside other building materials stocks.

The setup here depends on tariff clarity and panel pricing holding, risks that sit outside company control and could compress margins if Chinese capacity floods secondary markets.

3. Newmont Corporation (NEM)

Stock Pixie Score 7.5/10 | ROIC 36.9% | Revenue Growth 21.3% YoY | Insider Net Buying +30,406 Shares (6M)

Newmont delivers 36.9% ROIC and 53.2% gross margins with revenue up 21.3% year-over-year, a rare operating profile in large-cap gold. The stock trades at 18.08× earnings with an EV/EBITDA of 9.17, reflecting operational leverage to gold prices without distressed-asset discounts.

The normalized P/E (10Y) of 1.20 signals subdued historical earnings relative to current run rates, a reminder that gold miners live and die by spot prices. The 14% drawdown is shallow compared to the other names here.

Insiders added 30,406 net shares over six months, with Peter Wexler, Francois Hardy, and Mark C. Rodgers filing Form 4 activity in late February and early March. The net buy signals confidence, not panic selling.

Gold is a macro asset, and the thesis breaks if the dollar rallies or real rates rise faster than geopolitical risk premiums, outcomes Trump-era trade policy could trigger without warning.

What to Watch

• EBS: Any mpox case count acceleration or CDC procurement announcements that could unlock biodefense contract backlog.
• FSLR: Tariff policy clarity and Q1 panel pricing data, expected in April earnings.
• NEM: Gold spot price behavior if the Fed signals rate cuts or Trump posts shift dollar sentiment.
• Macro: Fear & Greed bouncing from extreme fear (18) back toward neutral (50) would confirm risk appetite returning to cyclicals.
• Sector: Any insider Form 4 activity beyond the names listed here, a signal worth tracking in high-conviction setups.

Go Deeper

The value screener hunts for companies trading below intrinsic value with the balance sheet and cash generation to recover. The top 3 show the scoring logic at work, but they don't show sector concentration risk, liquidity flags on smaller names, or the 15 tickers ranked 7.0–7.4 that didn't make the cut this week. Pro subscribers see the full ranked list, drawdown cohorts, and real-time Form 4 tracking.

See all value picks →